Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9604130 | 1.00 | CTDSP1 (0.40) | CTDSP1LMNAPOLBTSHRCYP1A2 | |
| SCHEMBL9604143 | 1.00 | CTDSP1 (0.40) | CTDSP1LMNAPOLBTSHRCYP1A2 | |
| SCHEMBL9604148 | 1.00 | CTDSP1 (0.40) | CTDSP1LMNAPOLBTSHRCYP1A2 | |
| SCHEMBL9604153 | 1.00 | CTDSP1 (0.40) | CTDSP1LMNAPOLBTSHRCYP1A2 | |
| SCHEMBL9604186 | 1.00 | CTDSP1 (0.40) | CTDSP1LMNAPOLBTSHRCYP1A2 | |
| SCHEMBL9604119 | 1.00 | CTDSP1 (0.40) | CTDSP1LMNAPOLBTSHRCYP1A2 | |
| SCHEMBL9604129 | 1.00 | CTDSP1 (0.40) | CTDSP1LMNAPOLBTSHRCYP1A2 | |
| SCHEMBL9604154 | 0.89 | CTDSP1 (0.49) | CTDSP1LMNAALDH1A1 | |
| SCHEMBL9604159 | 0.89 | CTDSP1 (0.49) | CTDSP1LMNAALDH1A1 | |
| SCHEMBL9604158 | 0.89 | CTDSP1 (0.49) | CTDSP1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157560-A1 | KETAL ESTERS OF ANHYDROPENTITOLS AND USES THEREOF | XL TERRA, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157560-A1 | KETAL ESTERS OF ANHYDROPENTITOLS AND USES THEREOF | XL TERRA, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120136070-A1 | KETAL ESTERS OF ANHYDROPENTITOLS AND USES THEREOF | XL TERRA, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120136070-A1 | KETAL ESTERS OF ANHYDROPENTITOLS AND USES THEREOF | XL TERRA, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136070-A1 | KETAL ESTERS OF ANHYDROPENTITOLS AND USES THEREOF | KHK, HKDC1, HK2 | CTDSP1 4006/4885LMNA 4298/4885POLB 4683/4885 |
| US-20120157560-A1 | KETAL ESTERS OF ANHYDROPENTITOLS AND USES THEREOF | KHK, HKDC1, HK2 | CTDSP1 4006/4885LMNA 4298/4885POLB 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.